BLUE Investors Have Opportunity to Lead bluebird bio, Inc. Securities Fraud Lawsuit
LOS ANGELES, April 15, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE).
Class Period: April 24, 2023 – December 8, 2023
Lead Plaintiff Deadline:May 28, 2024
If you are a shareholder who suffered a loss, click here to participate.
The complaint filed alleges that, throughout the Class Period, Defendants misled investors by creating the false impression that: (1) they could obtain FDA approval for lovo-cel without any black box warnings for haematological malignancies; (2) they would be granted a priority review voucher by the FDA and in turn sell it in order to strengthen their financial position for the lovo-cel launch; (3) as a result, the Company had significantly overstated Lyfgenia's clinical and/or commercial prospects; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Follow us for updates on Twitter: twitter.com/FRC_LAW.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View original content to download multimedia:https://www.prnewswire.com/news-releases/blue-investors-have-opportunity-to-lead-bluebird-bio-inc-securities-fraud-lawsuit-302116130.html
SOURCE The Law Offices of Frank R. Cruz, Los Angeles
Ausgewählte Hebelprodukte auf bluebird bio
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf bluebird bio
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle bluebird bio Aktie News
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
bluebird bio Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für bluebird bio nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 18.06.19 | bluebird bio Buy | Maxim Group | |
| 22.02.19 | bluebird bio Neutral | Cantor Fitzgerald | |
| 02.11.18 | bluebird bio Neutral | Cantor Fitzgerald | |
| 12.07.18 | bluebird bio Buy | Gabelli & Co | |
| 22.02.18 | bluebird bio Underweight | Cantor Fitzgerald |
